Brain Health

Determine Dementia Risk and Boost Brain Health

with Digital Vascular Biomarkers

Fast Facts

Cognitive Decline & Arterial Stiffening Go Hand-in-Hand

Brain Health and Arterial Stiffness

Arterial stiffness significantly impacts brain health, affecting cognitive functions and increasing stroke risk. Stiffer arteries can't buffer heartbeat forces, leading to elevated blood pressure and reduced cerebral blood flow. This can impair cognition and heighten the risk of vascular dementia. Additionally, increased arterial pressures may damage brain vessels and further elevating stroke risk. Therefore, monitoring and managing arterial stiffness is essential for optimal brain function.

Promote Cognitive Wellness

Vascular biomarkers reflect aging and stress, impacting cerebral blood flow and brain function. By monitoring these biomarkers, healthcare professionals can predict and manage risks of cerebrovascular diseases like stroke and dementia. Early detection enables timely interventions, from lifestyle changes to pharmacotherapy, to protect brain health. Continuous monitoring also helps assess treatment effectiveness in reducing arterial stiffness, enhancing cognitive function and overall neurological health.

Utility of Vascular Biomarkers in Brain Health

  • Bangen KJ, Smirnov DS, Delano-Wood L, et al.

    Elevated PWV is associated with poorer cognitive performance in older adults, particularly on memory tasks, in those who are at risk for AD.

    Bangen KJ, Smirnov DS, Delano-Wood L, et al.
    Alzheimer's Research & Therapy
  • Pase MP, Pipingas A, Kras M, Nolidin K, Gibbs AL,  et al.

    Pulse pressure was an independent predictor of both episodic secondary memory performance (P < 0.05) and speed of memory retrieval (P < 0.05). Augmentation index was also an independent predictor of speed of memory (P < 0.01).

  • Bangen KJ, Smirnov DS, Delano-Wood L, et al.

    Pulse wave velocity, a non-invasive method to assess arterial wall properties, may be a useful marker of risk for cognitive decline, particularly among individuals who are APOE ε4 carriers or CSF AD biomarker-positive.

    Bangen KJ, Smirnov DS, Delano-Wood L, et al.
    Alzheimer's Research & Therapy

1, 2, 3 Alzheimer's Disease International (ADI)